GFAP Promoter-Driven RNA Interference on TGF-β1 to Treat Liver Fibrosis

Author： Yang Ningning   Mahato Ram  

Publisher： Springer Publishing Company

ISSN： 0724-8741

Source： Pharmaceutical Research, Vol.28, Iss.4, 2011-04, pp. : 752-761

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cross-Talk Between TGF-β and NADPH Oxidases During Liver Fibrosis and Hepatocarcinogenesis

By  

Current Pharmaceutical Design, Vol. 21, Iss. 41, 2015-12 ,pp. : 5964-5976

Bentham Science Publishers

Access to resources Recommend Favorite

Editorial: [Hot Topic: TGF-β1 in Pre-Malignant and Malignant Liver Disease]

By  

Current Pharmaceutical Design, Vol. 18, Iss. 27, 2012-01 ,pp. : 4071-4071

Bentham Science Publishers

Access to resources Recommend Favorite

TGF-β in Epithelial to Mesenchymal Transition and Metastasis of Liver Carcinoma

By  

Current Pharmaceutical Design, Vol. 18, Iss. 27, 2012-09 ,pp. : 4135-4147

Bentham Science Publishers

Access to resources Recommend Favorite

TGF-&bgr;1 Signalling, Connecting Aberrant Inflammation and Colorectal Tumorigenesis

By  

Current Pharmaceutical Design, Vol. 18, Iss. 26, 2012-09 ,pp. : 3874-3888

Bentham Science Publishers

Access to resources Recommend Favorite

Angiotensin-TGF-&bgr;1 Crosstalk in Human Idiopathic Pulmonary Fibrosis:Autocrine Mechanisms in Myofibroblasts and Macrophages

By  

Current Pharmaceutical Design, Vol. 13, Iss. 12, 2007-04 ,pp. : 1247-1256

Bentham Science Publishers

Access to resources Recommend Favorite